Key facts
- Kinomica’s last known valuation is $16.6M.
- It has raised $13.1M; the latest was Later Stage VC ($5.6M) in Jul 2024.
- Notable investors include Innovate UK, Mercia Ventures, BGF (Financial Services), Puffin Point, Alderley Park — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Kinomica
- ·The full record, as it builds
Funding rounds
No funding rounds for Kinomica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kinomica
Developer of a phosphoproteomic diagnostic platform designed to enhance tailored treatment decisions involving anticancer drug therapies. The company's platform provides a suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can access direct activity measurements of multiple endogenous kinases and comprehensive cell signal network coverage, enabling patients to determine disease mechanisms, while upscaling drug targeting and biomarker identification.
- Sector
- Healthcare
- HQ
- Macclesfield, United Kingdom
- Founded
- 2016
- Employees
- 30
- Website
- kinomica.com/
- Ownership
- Privately Held (backing)
Kinomica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kinomica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kinomica in its N-PORT filings yet. We sweep new filings monthly.